How B cells influence bone biology in health and disease

Bone

Volumn 47, Issue 3, 2010, Pages 472-479

  Horowitz, Mark C ^a   Fretz, Jackie A ^a   Lorenzo, Joseph A ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

B cell activation; B cell differentiation; B cell transcription factors and bone; IL 7; Macrophage osteoclast differentiation; Regulation of B cell development by RANKL RANK signaling; Regulation of hematopoiesis by osteoblast lineage cells

Indexed keywords

ESTROGEN; HELIX LOOP HELIX PROTEIN; IKAROS TRANSCRIPTION FACTOR; INTERLEUKIN 7; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN EBF1; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR PU 1; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; BONE CELL; BONE DEVELOPMENT; BONE DISEASE; BONE REMODELING; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; INFECTION; INFLAMMATORY DISEASE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; MOLECULAR INTERACTION; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; B-LYMPHOCYTES; BONE AND BONES; BONE DISEASES, METABOLIC; CELL DIFFERENTIATION; ESTROGENS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNE SYSTEM; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 77955851132     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.06.011     Document Type: Review

References (80)

1. Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846.
2. Visnjic D., Kalajzic Z., Rowe D.W., Katavic V., Lorenzo J., Aquila H.L. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood 2004, 103:3258-3264.
3. Zhu J., Garrett R., Jung Y., Zhang Y., Kim N., Wang J., et al. Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood 2007, 109:3706-3712.
4. Kondo M., Wagers A.J., Manz M.G., Prohaska S.S., Sherer D.C., Beilhack G.F., et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol 2003, 21:759-806.
5. Medina K.L., Pongubala J.M.R., Reddy K.L., Lancki D.W., DeKoter R., Kieslinger M., et al. Assembling a gene regulatory network for specification of the B cell fate. Dev Cell 2004, 7:607-617.
6. Ghia P., ten Boekel E., Rolink A.G., Melchers F. B-cell development: a comparison between mouse and man. Immunol Today 1998, 19:480-485.
7. Hesslein D.G., Schatz D.G. Factors and forces controlling V(D)J recombination. Adv Immunol 2001, 78:169-232.
8. Hardy R.R., Hayakawa K. B cell development pathways. Annu Rev Immunol 2001, 19:595-621.
9. Li Y.S., Wasserman R., Hayakawa K., Hardy R.R. Identification of the earliest B lineage stage in mouse bone marrow. Immunity 1996, 5:527-535.
10. Rolink A., Haasner D., Melchers F., Anderson J. The surrogate light chain in mouse B-cell development. Int Rev Immuno 1996, 13:341-356.
11. Nemazee D. Receptor editing in B cells. Adv Immunol 2000, 74:89-126.
12. Bain G., Maandag E.C., Izon D.J., Amsen D., Kruisbeek A.M., Weintraub B.D., et al. E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell 1994, 79:885-892.
13. Lin H., Grosschedl R. Failure of B-cell differentiation in mice lacking the transcription factor EBF. Nature 1995, 376:263-267.
14. Adams B., Dorfler P., Aguzzi A., Kozmik Z., Urbanek P., Maurer-Fogy I., et al. Pax5 encodes the transcription factor BSAP and is expressed in B-lymphocytes, the developing CNS, and adult testis. Genes Dev 1992, 6:1589-1607.
15. Nutt S.L., Heavey B., Rolink A.G., Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 1999, 401:556-562.
16. sα-dependent signaling pathways. Proc Natl Acad Sci U S A 2008, 105:16976-16981.
17. Namen A.E., Lupton S., Hjerrild K., Wignall J., Mochizuki D.Y., Schmierer A., et al. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 1988, 333:571-573.
18. Mazzucchelli R.M., Durum S.K. Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol 2007, 7:144-154.
19. Miyaura C., Onoe Y., Inada M., Maki K., Ikuta K., Ito M., et al. Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency. Proc Natl Acad Sci U S A 1997, 94:9360-9365.
20. Weitzmann M.N., Roggia C., Toraldo G., Weitzmann L., Pacifici R. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 2002, 110:1643-1650.
21. Weitzmann M.N., Cenci S., Rifas L., Brown C., Pacifici R. Interleukin-7 stimulates osteoclast formation by up-regulating the T- cell production of soluble osteoclastogenic cytokines. Blood 2000, 96:1873-1878.
22. Salopek D., Grcevic D., Katavic V., Kovacic N., Lukic I.K., Marusic A. Increased bone resorption and osteopenia are a part of the lymphoproliferative phenotype of mice with systemic over-expression of interleukin-7 gene driven by MHC class II promoter. Immunol Lett 2008, 121:134-139.
23. Toraldo G., Roggia C., Qian W.P., Pacifici R., Weitzmann M.N. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci U S A 2003, 100:125-130.
24. Gendron S., Boisvert M., Chetoui N., Aoudjit F. Alpha1beta1 integrin and interleukin-7 receptor up-regulate the expression of RANKL in human T cells and enhance their osteoclastogenic function. Immunology 2008, 125:359-369.
25. Lee S.K., Kalinowski J.F., Jastrzebski S.L., Puddington L., Lorenzo J.A. Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis. Endocrinology 2003, 144:3524-3531.
26. Lee S.K., Kalinowski J.F., Jacquin C., Adams D.J., Gronowicz G., Lorenzo J.A. Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. J Bone Miner Res 2006, 21:695-702.
27. Ryan M.R., Shepherd R., Leavey J.K., Gao Y., Grassi F., Schnell F.J., et al. An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc Natl Acad Sci U S A 2005, 102:16735-16740.
28. Sato T., Watanabe K., Masuhara M., Hada N., Hakeda Y. Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro. J Bone Miner Metab 2007, 25:19-27.
29. Lee S., Kalinowski J.F., Adams D.J., Aguila H.L., Lorenzo J.A. Osteoblast specific overexpression of human interleukin-7 increases femoral trabecular bone mass in female mice and inhibits in vitro osteoclastogenesis. J Bone Miner Res 2004, 19:S410.
30. Lee S., Kalinowski J.F., Adams D.J., Aguila H.L., Lorenzo J.A. Osteoblast specific overexpression of human interlukin-7 rescues the bone phenotype of interleukin-7 deficient female mice. J Bone Miner Res 2005, 20:S48.
31. Scott E.W., Simon M.C., Anastasi J., Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 1994, 265:1573-1577.
32. Tondravi M.M., McKercher S.R., Anderson K., Erdmann J.M., Quiroz M., Maki R., et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature 1997, 386:81-84.
33. Scott E.W., Fisher R.C., Olson M.C., Kehrli E.W., Simon M.C., Singh H. PU.1 functions in a cell-autonomous manner to control the differentiation of multipotential lymphoid-myeloid progenitors. Immunity 1997, 6:427-447.
34. DeKoter R.P., Walsh J.C., H.Singh Pu.1 regulates both cytokine-dependent proliferation and differentiation of granulocyte/macrophage progenitors. EMBO J 1998, 17:4456-4468.
35. DeKoter R.P., Singh H. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science 2000, 288:1439-1441.
36. DeKoter R.P., Lee H.-J., H.Singh Pu.1 regulates expression of the interleukin-7 receptor in lymphoid progenitors. Immunity 2002, 16:297-309.
37. Klemsz M.J., McKercher S.R., Celada A., Van Beveren C., Maki R.A. The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene. Cell 1990, 61:113-124.
38. Ross I.L., Dunn T.l., Yue X., Roy S., Barnett C.J., Hume Da. Comparison of the expression and function of the transcription factor PU.1 (Spi-1 proto-oncogene) between murine macrophages and B lymphocytes. Oncogene 1994, 9:121-132.
39. Georgopoulos K. Haematopoietic cell-fate decisions, chromatin regulation and Ikaros. Nat Rev Immunol 2002, 2:162-174.
40. Cobb B.S., Smale S.T. Ikaros-family proteins: in search of molecular functions during lymphocytes development. Curr Top Microbiol Immunol 2005, 290:29-47.
41. Kelley C.M., Ikeda T., Koipally J., Avitahl N., Wu L., Georgopoulos K., et al. Helios, a novel dimerization partner of Ikaros expressed in the earliest hematopoietic progenitors. Curr Biol 1998, 8:508-515.
42. Georgopoulos K., Bigby M., Wang J.H., Molnar A., Wu P., Winandy S., et al. The Ikaros gene is required for the development of all lymphoid lineages. Cell 1994, 79:143-156.
43. Wang J.H., Nichogiannopoulou A., Wu L., Sun L., Sharpe A.H., Bigby M., et al. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity 1996, 5:537-549.
44. Georgopoulos K., Winady S., Avitahl N. The role of the Ikaros gene in lymphocyte development and homeostasis. Annu Rev Immunol 1997, 15:155-176.
45. Reynaud D., Demarco I.A., Reddy K.L., Schjerven H., Bertolino E., Chen Z., et al. Regulation of B cell fate commitment and immunoglobulin heavy-chain gene rearrangements by Ikaros. Nat Immunol 2008, 9:927-936.
46. Murre C., McCaw P.S., Baltimore D. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 1989, 56:777-783.
47. Semerad C.L., Mercer E.M., Inlay M.A., Weissman I.L., Murre C. E2A proteins maintain the hematopoietic stem cell pool and promote the maturation of myelolymphoid and myeloerythroid progenitors. Proc Natl Acad Sci U S A 2009, 106:1930-1935.
48. Zhuang Y., Jackson A., Pan L., Shen K., Dai M. Regulation of E2A gene expression in B-lymphocyte development. Mol Immunol 2004, 40:1165-1177.
49. Pongubala J.M., Northrup D.L., Lancki D.W., Medina K.L., Treiber T., Bertolino E., et al. Transcription factor EBF restricts alternative lineage options and promotes B cell fate commitment independently of Pax5. Nat Immunol 2008, 9:203-215.
50. Hesslein D.G.T., Fretz J.A., Xi Y., Nelson T., Zhou S., Lorenzo J.A., et al. Ebf1 dependent control of the osteoblast and adipocyte lineages. Bone 2009, 44:537-546.
51. Akerblad P., Lind U., Liberg D., Bamberg K., Sigvardsson M. Early B-cell factor (O/E-1) is a promoter of adipogenesis and involved in control of genes important for terminal adipocyte differentiation. Mol Cell Biol 2002, 22:8015-8025.
52. Urbanek P., Wang Z., Fetka I., Wagner E., Busslinger M. Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP. Cell 1994, 79:901-912.
53. Horowitz M.C., Xi Y., Pflugh D.L., Hesslein D.G.T., Schatz D.G., Lorenzo J.A., et al. Pax5 deficient mice exhibit early onset osteoporosis with increased osteoclast progenitors. J Immunol 2004, 173:6583-6591.
54. Nutt S.L., Heavey B., Rolink A.G., Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 1999, 401:556-562.
55. Montecino-Rodriguez E., Leathers H., Dorshkind K. Bipotential B-macrophage progenitors are present in adult bone marrow. Nat Immunol 2001, 2:83-88.
56. Lee S.-K., Kadono Y., Okada F., Jacquin C., Koczon-Jaremko B., Gronowicz G., et al. T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy. J Bone Miner Res 2006, 21:1704-1712.
57. Li Y., Toraldo G., Li A., Yang X., Zhang H., Qian W.-P., et al. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 2007, 109:3839-3848.
58. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.
59. Kong Y.-Y., Yoshida H., Sarosi I., Tan H.-L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
60. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999, 13:2412-2424.
61. Lomaga M.A., Yeh W.-C., Sarosi I., Duncan G.S., Furlonger C., Ho A., et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999, 15:1015-1024.
62. Yun T.J., Tallquist M.D., Aicher A., Rafferty K.L., Marshall A.J., Moon J.J., et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 2001, 166:1482-1491.
63. Blin-Wakkach C., Wakkach A., Rochet N., Carle G.F. Characterization of a novel bipotent hematopoietic progenitor population in normal and osteopetrotic mice. J Bone Miner Res 2004, 19:1137-1143.
64. Kanematsu M., Sato T., Takai H., Watanabe K., Ikeda K., Yamada Y. Prostaglandin E 2 induces expression of receptor activator of nuclear factor-kappaB ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res 2000, 15:1321-1329.
65. Katavic V., Grcevic D., Lee S.K., Kalinowski J., Jastrzebski S., Dougall W., et al. The surface antigen CD45R identifies a population of estrogen-regulated murine marrow cells that contain osteoclast precursors. Bone 2003, 32:581-590.
66. Sato T., Shibata T., Ikeda K., Watanabe K. Generation of bone-resorbing osteoclasts from B220+ cells: its role in accelerated osteoclastogenesis due to estrogen deficiency. J Bone Miner Res 2001, 16:2215-2221.
67. Jacquin C., Gran D.E., Lee S.K., Lorenzo J.A., Aguila H.L. Identification of multiple osteoclast precursor populations in murine bone marrow. J Bone Miner Res 2006, 21:67-77.
68. Li Y., Li A., Yang X., Weitzmann M.N. Ovariectomy-induced bone loss occurs independently of B cells. J Cell Biochem 2007, 100:1370-1375.
69. Kincade P.W., Medina K.L., Payne K.J., Rossi M.I., Tudor K.S., Yamashita Y., et al. Early B-lymphocyte precursors and their regulation by sex steroids. Immunol Rev 2000, 175:128-137.
70. Masuzawa T., Miyaura C., Onoe Y., Kusano K., Ohta H., Nozawa S., et al. Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. J Clin Invest 1994, 94:1090-1097.
71. Anderson D.M., Maraskovsky E., Billingsley W.L., Cougall W.C., Tometsko M.E., Roux E.R., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179.
72. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111:1221-1230.
73. Schett G. Osteoimmunology in rheumatic diseases. Arthritis Res Ther 2009, 11:210.
74. Kawai T., Matsuyama T., Hosokawa Y., Makihira S., Seki M., Karimbux N.Y., et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 2006, 169(3):987-998.
75. Hayer S., Polzer K., Brandl A., Zwerina T., Kireva T., Smolen J.S., et al. B-cell infiltrates induce endosteal bone formation in inflammatory arthritis. J Bone Miner Res 2008, 23:1650-1660.
76. Ehrhardt G.R., Hijikata A., Kitamura H., Ohara O., Wang J.Y., Cooper M.D. Discriminating gene expression profiles of memory B cell subpopulations. J Exp Med 2008, 205:1807-1817.
77. Roodman G.D. Pathogenesis of myeloma bone disease. J Cell Biochem 2010, 109:283-291.
78. Pearse R.N., Sordillo E.M., Yaccoby S., Wong B.R., Liau D.F., Colman N., et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001, 98:11581-11586.
79. Sezer O., Heider U., Jakob C., Zavrski I., Eucker J., Possinger K., et al. Immunocytochemistry reveals RAANKL expression of myeloma cells. Blood 2002, 99:4646-4647.
80. Shibata H., Abe M., Hiura K., Wilde J., Moriyama K., Sano T., et al. Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-kappaB ligand and vascular endothelial growth factor to enhance osteoclastogenesis. Clin Cancer Res 2005, 11:6109-6115.